Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is a chronic, frequently progressive condition that affects approximately three million people in the U.S. IBD is associated with significant morbidity, diminished quality of life, and, in some cases, mortality. To meet the persistent challenges associated with managing patients with moderate to severe IBD, health care professionals must be knowledgeable regarding the wide variety of existing and emerging agents to treat these diseases. Ongoing education is required to remain current regarding the evidence-based and expert-recommended strategies for managing IBD. In this CME activity, expert faculty describe the pathogenesis of IBD and the mechanisms of action of existing and novel therapies as well as assess the clinical evidence to support the safety and efficacy of emerging agents for treating patients with IBD. This activity will feature Rapid-Fire Roundtable, an engaging, fast-paced exchange of clinical expert perspectives to promote enhanced learning.
More information
Learning objectives
Upon successful completion of this educational activity, participants should be better able to:
- Describe the known pathways and mechanisms that contribute to the pathogenesis of Crohn’s disease and ulcerative colitis.
- Compare the mechanisms of action of currently available agents versus novel emerging agents for the management of moderate to severe IBD.
- Assess the clinical evidence regarding the safety and efficacy of emerging agents for the treatment of IBD.
Course Director
Activity Chair
David T. Rubin, MD, AGAF
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, Illinois
Faculty
Britt Christensen, BSc, MBBS (Hons), MPH
Head of Inflammatory Bowel Disease
Gastroenterology Department
The Royal Melbourne Hospital
Melbourne, Australia
Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, North Carolina
Alan C. Moss, MD, AGAF
Director, Crohn's & Colitis Program
Boston Medical Center
Boston University
Boston, Massachuetts
Accreditation and designation
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures
Activity Chair and Faculty report the following relationship(s)
Britt Christensen, BSc, MBBS (Hons), MPH
Consulting Fee: Gilead, Novartis
Speakers Bureau: AbbVie, Janssen, Pfizer, Takeda
Millie D. Long, MD, MPH
Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
Alan C. Moss, MD, AGAF
Consulting Fee: Janssen, Pfizer
David T. Rubin, MD, AGAF
Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Ichnos Sciences, Janssen, Lilly, Mahana Therapeutics, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions, Techlab, Inc.
Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
Ownership Interest: AbGenomics, Biomica
Board of Trustees: American College of Gastroenterology
Co-Founder: Cornerstone Health, Inc., GoDuRun, LLC
Reviewers report the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Linda A. Giarraputo PA-C
No relevant financial relationships to disclose.
The American Gastroenterological Association and Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at the American Gastroenterological Association and Vindico Medical Education, Office of Medical Affairs and Compliance.
